123 related articles for article (PubMed ID: 24205719)
1. [Familial type III hyperlipoproteinemia].
Eto M; Saito M
Nihon Rinsho; 2013 Sep; 71(9):1590-4. PubMed ID: 24205719
[TBL] [Abstract][Full Text] [Related]
2. Serum remnant lipoprotein cholesterol/triglyceride ratio as an index for screening familial type III hyperlipidaemia.
Nakajima K; Daimon M; Kamiyama K; Takanashi K; Suzuki Y; Watanabe M; Kubono K; Saniabadi AR; Takashima S; Sakurabayashi I
Ann Clin Biochem; 2007 Jul; 44(Pt 4):353-9. PubMed ID: 17663088
[TBL] [Abstract][Full Text] [Related]
3. Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan.
Eto M; Saito M; Nakata H; Iwashima Y; Watanabe K; Ikoda A; Kaku K
Clin Genet; 2002 Jun; 61(6):416-22. PubMed ID: 12121348
[TBL] [Abstract][Full Text] [Related]
4. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
Saito M; Eto M; Kaku K
Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
[TBL] [Abstract][Full Text] [Related]
5. Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia.
Wang T; Nakajima K; Leary ET; Warnick GR; Cohn JS; Hopkins PN; Wu LL; Cilla DD; Zhong J; Havel RJ
Clin Chem; 1999 Nov; 45(11):1981-7. PubMed ID: 10545069
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
[TBL] [Abstract][Full Text] [Related]
8. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
Stuyt PM; Demacker PN; van't Laar A
Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype.
Todo Y; Kobayashi J; Higashikata T; Kawashiri M; Nohara A; Inazu A; Koizumi J; Mabuchi H
Clin Chim Acta; 2004 Oct; 348(1-2):35-40. PubMed ID: 15369733
[TBL] [Abstract][Full Text] [Related]
10. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
11. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
13. [Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patient].
Ziemer A; Göring HD
Hautarzt; 1993 Aug; 44(8):538-44. PubMed ID: 8376110
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
15. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
[TBL] [Abstract][Full Text] [Related]
16. Familial apolipoprotein E deficiency.
Schaefer EJ; Gregg RE; Ghiselli G; Forte TM; Ordovas JM; Zech LA; Brewer HB
J Clin Invest; 1986 Nov; 78(5):1206-19. PubMed ID: 3771793
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner G; Kurth B; Lohrmann J
Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
[TBL] [Abstract][Full Text] [Related]
18. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
Murase T; Okubo M; Takeuchi I
J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
20. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin.
East CA; Grundy SM; Bilheimer DW
Metabolism; 1986 Feb; 35(2):97-8. PubMed ID: 3633017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
